These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12625408)

  • 21. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency.
    Smith JC; Lang D; McEneny J; Evans LM; Scanlon MF; Young I; Davies J
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):449-55. PubMed ID: 11966737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence of growth hormone deficiency in survivors of subarachnoid haemorrhage: results from a large single centre study.
    Giritharan S; Cox J; Heal CJ; Hughes D; Gnanalingham K; Kearney T
    Pituitary; 2017 Dec; 20(6):624-634. PubMed ID: 28822018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia.
    Ho KK;
    Eur J Endocrinol; 2007 Dec; 157(6):695-700. PubMed ID: 18057375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of fuel metabolism during exercise in hypopituitarism with growth hormone-deficiency (GHD).
    Zueger T; Loher H; Egger A; Boesch C; Christ E
    Growth Horm IGF Res; 2016 Aug; 29():39-44. PubMed ID: 27084998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
    Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adults with partial growth hormone deficiency have an adverse body composition.
    Murray RD; Adams JE; Shalet SM
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1586-91. PubMed ID: 15070916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities.
    Abdu TA; Neary R; Elhadd TA; Akber M; Clayton RN
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):209-16. PubMed ID: 11531927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver.
    Takahashi Y
    Endocr J; 2012; 59(11):955-62. PubMed ID: 22986486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).
    Rochira V; Mossetto G; Jia N; Cannavo S; Beck-Peccoz P; Aimaretti G; Ambrosio MR; Di Somma C; Losa M; Ferone D; Lubrano C; Scaroni C; Giampietro A; Corsello SM; Poggi M
    J Endocrinol Invest; 2018 Nov; 41(11):1259-1266. PubMed ID: 29536433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables.
    Abrams P; Boquete H; Fideleff H; Feldt-Rasmussen U; Jönsson PJ; Koltowska-Häggström M; Wilton P; Abs R
    Eur J Endocrinol; 2008 Dec; 159(6):825-32. PubMed ID: 18713841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.
    Colao A; Cerbone G; Pivonello R; Aimaretti G; Loche S; Di Somma C; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1277-82. PubMed ID: 10199767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).
    Pincelli AI; Bragato R; Scacchi M; Branzi G; Osculati G; Viarengo R; Leonetti G; Cavagnini F
    J Endocrinol Invest; 2003 May; 26(5):420-8. PubMed ID: 12906369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.
    Joaquin C; Aguilera E; Granada ML; Pastor MC; Salinas I; Alonso N; Sanmartí A
    Eur J Endocrinol; 2008 Apr; 158(4):483-90. PubMed ID: 18362295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRENDS IN GROWTH HORMONE STIMULATION TESTING AND GROWTH HORMONE DOSING IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: RESULTS FROM THE ANSWER PROGRAM.
    Gordon MB; Levy RA; Gut R; Germak J
    Endocr Pract; 2016 Apr; 22(4):396-405. PubMed ID: 26574788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone.
    Deutschbein T; Bidlingmaier M; Schopohl J; Strasburger CJ; Petersenn S
    Eur J Endocrinol; 2017 Mar; 176(3):273-281. PubMed ID: 27932410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis.
    Colao A; Di Somma C; Spiezia S; Rota F; Pivonello R; Savastano S; Lombardi G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2191-200. PubMed ID: 16537686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of growth hormone and adrenocorticotropic hormone deficiencies in patients with prenatal or perinatal-onset hypothalamic hypopituitarism having invisible or thin pituitary stalk on magnetic resonance imaging.
    Miyamoto J; Hasegawa Y; Ohnami N; Onigata K; Kinoshita E; Nishi Y; Tachibana K; Hasegawa T
    Endocr J; 2001 Jun; 48(3):355-62. PubMed ID: 11523907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population.
    Granada ML; Murillo J; Lucas A; Salinas I; Llopis MA; Castells I; Foz M; Sanmartí A
    Eur J Endocrinol; 2000 Mar; 142(3):243-53. PubMed ID: 10700718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.